Company: IMRX
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0001790340-25-000042
Chunk: 110

Company: Immuneering Corp
Filing Date: 2025-03-20
Form: 10-K
Item: Item 8
Chunk 110
---
—— 4,236,078 — — 4,237,397 Issuance of common stock through employee stock purchase plan230,768230 —— 374,422 — — 374,652 Stock-based compensation expense—— —— 6,501,366 — — 6,501,366 Net loss—— —— — — (61,036,608)(61,036,608)Other comprehensive income—— —— — 778 — 778 Balance at December 31, 202431,050,448$31,050 —$— $265,650,362 $— $(224,295,186)$41,386,226 

The accompanying notes are an integral part of these consolidated financial statements.

122

IMMUNEERING CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEAR ENDED DECEMBER 31, 2024 and 2023

20242023Cash flows from operating activities:Net loss$(61,036,608)$(53,471,622)Adjustment to reconcile to net loss to net cash used in operating activities:Depreciation expense355,807 322,816 Reduction in carrying amount of right-of-use assets328,377 412,055 Amortization of intangibles29,267 29,267 Stock-based compensation expense6,501,366 5,727,135 Net accretion of discount on marketable securities(259,181)(1,017,583)Loss on disposal of fixed assets6,784 3,939 Change in assets and liabilities:(Increase) decrease in:Accounts receivable— 12,417 Prepaid expenses and other current assets(24,865)(172,660)Other assets(261,337)(290,742)Increase (decrease) in:Accounts payable(112,143)(1,106,896)Accrued expenses(200,831)721,989 Lease liabilities(300,102)(378,723)Other liabilities(26,105)239,974 Net cash used in operating activities(54,999,571)(48,968,634)Cash flows from investing activities:Purchases of property and equipment(84,875)(342,746)Purchases of marketable securities(5,410,170)(44,660,762)Maturities of marketable securities